Octreotide inhibits choroidal neovascularization in rats

Ophthalmic Research

Volumn 42, Issue 1, 2009, Pages 36-42

  Qu, Yi ^a   Zhang, Shuihua ^b   Xu, Xiaoyi ^a   Wang, Hong ^a   Li, Jinghai ^a   Zhou, Fang ^a   Wei, Fengcai ^a  

^a SHANDONG UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Choroidal neovascularization, rats; Choroidal neovascularization, therapeutics; Octreotide

Indexed keywords

COMPLEMENTARY DNA; FLUORESCEIN; MESSENGER RNA; OCTREOTIDE; SOMATOMEDIN C; VASCULOTROPIN; VISUAL PIGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG TARGETING; EYE; FLUORESCENCE ANGIOGRAPHY; LASER COAGULATION; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; QUANTITATIVE ANALYSIS; RAT; REPEATED DRUG DOSE; RETROLENTAL FIBROPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; INSULIN-LIKE GROWTH FACTOR I; MALE; OCTREOTIDE; RATS; RATS, INBRED BN; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66149151772     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000219683     Document Type: Article

References (44)

1. Zou HD, Zhang X, Xu X, Wang FH, Zhang SJ: Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai (in Chinese). Zhonghua Yan Ke Za Zhi 2005; 41:15-19.
2. Friedman DS, O'Colmain BJ, Munoz B, To-many SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
3. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP: Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-293.
4. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
5. Campochiaro PA: Retinal and choroidal neovascularization. J Cell Physiol 2000;184: 301-310.
6. Eyetech Study Group: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110: 979-986.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizu-mab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-1431.
9. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU: Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophtha lmol Vis Sci 2006;47:4569-4578.
10. Campochiaro PA: Targeted pharmacotherapy of retinal diseases with ranibizumab. Drugs Today (Barc) 2007;43:529-537.
11. Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, Schmidt-Erfurth U: Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144:886-892.
12. Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophtha lmol 2007;144:627-637.
13. Higgins RD, Yan Y, Schrier BK: Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 2002;74:553-559.
14. Grant MB, Caballero S: Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc) 2002;38:783-791.
15. Danesi R, Del Tacca M: The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996;45:49-50.
16. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997;3:265-272.
17. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993;55:446-450.
18. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit an-giogenesis in the chick chorioallantoic membrane. J Surg Res 1991;50: 245-251.
19. Baudouin C, Imbert F, Ettaiche M, Gastaud P: Evaluation of antiproliferative effects of the somatostatin analogue somatuline in a rabbit model of traction retinal detachment. Funda m Clin Pharmacol 1995;9:357-365.
20. Demir T, Celiker UO, Kukner A, Mogulkoc R, Celebi S, Celiker H: Effect of Octreotide on experimental corneal neovascularization. Acta Opht ha lmol Scand 1999;77:386-390.
21. Renno RZ, Youssri AI, Michaud N, Gragoudas ES, Miller JW: Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002;43:1574-1580.
22. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab 1992;18:438-444.
23. Wu PC, Liu CC, Chen CH, Kou HK, Shen SC, Lu CY, Chou WY, Sung MT, Yang LC: Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol 2003;241:63-69.
24. Yi X, Ogata N, Komada M, Yamamoto C, Takahashi K, Omori K, Uyama M: Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 1997;235:313-319.
25. Lambooij AC, van Wely KH, Lindenbergh-Kortleve DJ, Kuijpers RW, Kliffen M, Mooy CM: Insulin-like growth factor-1 and its receptor in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2003;44:2192-2198.
26. Rosenthal R, Wohlleben H, Malek G, Schlichting L, Thieme H, Bowes Rickman C, Strauss O: Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration. Biochem Biophys Res Commun 2004;323:1203-1208.
27. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT: Increased expression of angiogenic growth factors in age-related maculop-athy. Br J Ophthalmol 1997;81:154-162.
28. Yanagi Y, Tamaki Y, Inoue Y, Obata R, Muranaka K, Homma N: Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase. Invest Ophthalmol Vis Sci 2003;44:751-754.
29. Edelman JL, Castro MR: Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp Eye Res 2000;71: 523-533.
30. Campos M, Amaral J, Becerra SP, Fariss RN: A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2006;47:5163-5170.
31. Leske DA, Wu J, Fautsch MP, Karger RA, Berdahl JP, Lanier WL, Holmes JM: The role of VEGF and IGF-1 in a hypercarbic oxygeninduced retinopathy rat model of ROP. Mol Vis 2004;10:43-50.
32. Lin CT, Li HZ, Wu JY: Immunocytochemical localization of L-glutamate decarboxylase, 7-aminobutyric acid transaminase, cysteine sulfinic acid decarboxylase, aspartate aminotransferase and somatostatin in rat retina. Brain Res 1983;270:273-283.
33. Johnson J, Rickman DW, Brecha NC: Somatostatin and somatostatin subtype 2A expression in the mammalian retina. Microsc Res Tech 2000;50:103-111.
34. Luo Q, Peyman GA, Conway MD, Woltering EA: Effect of a somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res 1996;15:909-913.
35. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J: Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001;92: 545-550.
36. Van Hagen PM, Baarsma GS, Mooy CM, Ercoskan EM, ter Averst E, Hofland LJ, Lamberts SW, Kuijpers RW: Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 2000;143(suppl 1):S43-S51.
37. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR: Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-868.
38. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE: Overexpression of vascular endothelial growth factor in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-144.
39. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, Poulaki V, Ma JJ, Redmond TM, Liu S, Adamis AP, D'Amato RJ: Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001;158: 1161-1172.
40. Slomiany MG, Rosenzweig SA: IGF-1-in-duced VEGF and IGFBP-3 secretion correlates with increased HIF-1α expression and activity in retinal pigment epithelial cell line D407. Invest Ophthalmol Vis Sci 2004;45: 2838-2847.
41. Slomiany MG, Rosenzweig SA: Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol 2004;287:C746-C753.
42. Spraul CW, Baldysiak-Figiel A, Lang GK, Lang GE: Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch Clin Exp Ophthalmol 2002;240:227-231.
43. Sall JW, Klisovic DD, O'Dorisio MS, Katz SE: Somatostatin inhibits IGF-1-mediated induction of VEGF in human retinal pigment epit helia l cel ls. Exp Eye Res 2004;79:465-476.
44. Bezerra Y, Fuselier JA, Peyman GA, Oner H, Drouant G, Coy DH: Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin conjugate on laser-induced choroidal neovascularization in rats. Retina 2005;25:345-354.